Gowling WLG’s Life Sciences team has advised Argenx on its collaboration with global biopharmaceutical company AbbVie to develop ARGX-115, a potential treatment for cancer.
Patrick Duxbury, head of life sciences, worked with associate Elwin Morgan on the collaboration agreement. Patrick worked closely with senior VP of business development at argenx, Dr Debbie Allen and with CEO Tim van Hauwermeiren.